| Regulatory status | PHASE 3 |
|---|---|
| Mechanism | Dual glucagon / GLP-1 receptor agonist |
| Developer | Boehringer Ingelheim / Zealand Pharma |
| Form | Lyophilized powder · 2mg, 5mg, 10mg, 15mg |
| CAS | 2803840-27-9 |
| Purity docs | Batch-matched COA available on request — ask us. |
| Ships from | Ontario, Canada |
| Intended use | Laboratory research only. Not for human consumption. |
Survodutide pairs GLP-1 agonism with glucagon receptor agonism — the glucagon component increases energy expenditure while GLP-1 suppresses intake. It is in the phase 3 SYNCHRONIZE program for obesity, with additional trials in metabolic liver disease.
Lyophilized vials: keep sealed, dry, and away from light and heat. Refrigeration at 2–8°C is the best default; −20°C for long-term storage. After reconstitution: refrigerate at 2–8°C and use promptly — no beyond-use date is validated.
GLP-1 appetite control plus glucagon-driven energy expenditure.
New here? Read the beginner's guide →
$15 flat shipping Canada-wide · free over $200
The active ingredient in Ozempic and Wegovy — the original once-weekly weight-loss medicine.
GLP-1 receptor agonist
The active ingredient in Mounjaro and Zepbound — the newer, stronger once-weekly weight-loss medicine.
Dual GIP / GLP-1 receptor agonist
A once-weekly weight-loss medicine already approved in China — still experimental in Canada and the US.
Dual GLP-1 / glucagon receptor agonist
